We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.09B
AUM Growth
+$551M
Cap. Flow
+$510M
Cap. Flow %
24.34%
Top 10 Hldgs %
59.78%
Holding
66
New
16
Increased
22
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.8M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$50.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$44.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.8M
5
DERM
Dermira, Inc.
DERM
+$41.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$56.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.8M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$9.2M
5
AGEN
Agenus
AGEN
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 83.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
$17.8M 0.85%
529,943
+25,000
+5% +$795K
INDP icon
27
Indaptus Therapeutics
INDP
$175M
$13.9M 0.67%
980
– –
BDSI
28
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$12.2M 0.58%
5,437,779
+2,968,291
+120% +$6.95M
JNCE
29
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$11.7M 0.56%
+523,174
New +$11.6M
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$11.2M 0.54%
4,692,343
+800,000
+21% +$2.66M
AVEO
31
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$9.37M 0.45%
323,189
-77,500
-19% -$2.27M
STML
32
DELISTED
Stemline Therapeutics, Inc.
STML
$8.02M 0.38%
+524,321
New +$8.17M
ONCS
33
DELISTED
OncoSec Medical Incorporated
ONCS
$7.53M 0.36%
+18,217
New +$7.47M
KPTI icon
34
Karyopharm Therapeutics
KPTI
$44.6M
$7.52M 0.36%
+37,377
New +$7.45M
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$7.45M 0.36%
396,635
– –
ACAD icon
36
Acadia Pharmaceuticals
ACAD
$4.39B
$7.13M 0.34%
+317,100
New +$8.78M
ALIM
37
DELISTED
Alimera Sciences
ALIM
$6.43M 0.31%
416,105
– –
VIVE
38
DELISTED
VIVEVE MED INC
VIVE
$5.61M 0.27%
1,533
+500
+48% +$2.17M
VRAY
39
DELISTED
ViewRay, Inc.
VRAY
$4.04M 0.19%
730,161
– –
TNDM icon
40
Tandem Diabetes Care
TNDM
$1.38B
$3.89M 0.19%
+783,910
New +$2.53M
FOLD
41
CALL
DELISTED
Amicus Therapeutics
FOLD
$3.76M 0.18%
2,350,100
+850,100
+57% +$12.9M
DOVA
42
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$3.39M 0.16%
+125,000
New +$3.74M
AGEN
43
Agenus
AGEN
$326M
$3.32M 0.16%
35,897
-88,398
-71% -$7.85M
FENC icon
44
Fennec Pharmaceuticals
FENC
$333M
$3.28M 0.16%
272,666
+66,666
+32% +$630K
SLDB icon
45
Solid Biosciences
SLDB
$790M
$2.06M 0.1%
+18,333
New +$6.19M
QURE icon
46
uniQure
QURE
$3.06B
$1.59M 0.08%
+67,758
New +$1.48M
GBT
47
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.44M 0.07%
+152,000
New +$8.48M
XBI icon
48
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$998K 0.05%
+750,000
New +$68.5M
VCYT icon
49
Veracyte
VCYT
$3.61B
$665K 0.03%
119,680
-632,775
-84% -$3.92M
OTLK icon
50
Outlook Therapeutics
OTLK
$171M
$608K 0.03%
4,272
– –
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Avoro Capital Advisors held 66 positions worth $2.09B, up 36% from $1.54B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $510M of net new capital in Q1 2018, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Puma Biotechnology: 825,368 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $56.8M trimmed.

  • Avoro Capital Advisors's largest Q1 2018 buy was Puma Biotechnology: 825,368 shares worth $56.2M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q1 2018, an estimated $44.8M increase.
  • Avoro Capital Advisors's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $56.8M.
  • Avoro Capital Advisors fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $28M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $2.09B portfolio in Q1 2018.
  • Avoro Capital Advisors opened 16 new positions and closed 10 in Q1 2018.
  • Avoro Capital Advisors's portfolio value rose 36% quarter-over-quarter to $2.09B.

Based on Avoro Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.